Compare ANGI & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANGI | LXRX |
|---|---|---|
| Founded | 1995 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 266.7M | 660.9M |
| IPO Year | 2017 | 2000 |
| Metric | ANGI | LXRX |
|---|---|---|
| Price | $7.34 | $1.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $17.00 | $4.15 |
| AVG Volume (30 Days) | 876.0K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1242.86 | 77.78 |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $736,386,000.00 | $49,803,000.00 |
| Revenue This Year | $3.25 | N/A |
| Revenue Next Year | $3.76 | N/A |
| P/E Ratio | $7.73 | ★ N/A |
| Revenue Growth | 47.60 | ★ 60.24 |
| 52 Week Low | $6.43 | $0.49 |
| 52 Week High | $19.42 | $1.86 |
| Indicator | ANGI | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.48 | 64.34 |
| Support Level | $6.43 | $1.07 |
| Resistance Level | $8.19 | N/A |
| Average True Range (ATR) | 0.40 | 0.10 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 64.28 | 98.61 |
Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.